HomeIndustriesHealthcareNovo Nordisk (NVO) Stock Rallies After Ozempic Trial Success For Kidney Problems

Novo Nordisk (NVO) Stock Rallies After Ozempic Trial Success For Kidney Problems

Novo Nordisk (NVO) rallies after Ozempic trial success for kidney problems. The trial included 3,500+ people with Type 2 Diabetes with two-thirds of patients at high risk of chronic kidney disease progress. NVO stopped the Ozempic trial early after positive results for kidney issues. Caroline Woods discusses this news. Tune in to find out more about the stock market today.

Morning Trade Live

11 Oct 2023

SHARE

ON AIR
3:00 pm
Market Overtime
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Liz Ann Live
REPLAY
1:30 pm
The Wrap
REPLAY
ON AIR
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor